Sarepta Therapeutics (SRPT): Valuation Update Following ELEVIDYS Label Changes and Heightened Safety Warnings

Simply Wall St.11-22

Sarepta Therapeutics (SRPT) announced major updates to the prescribing information for its gene therapy ELEVIDYS. These updates include a new boxed warning for acute serious liver injury risk and the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585179658?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-11-22 15:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585179658","market":"sg","top_or_hot":-1,"title":"Sarepta Therapeutics (SRPT): Valuation Update Following ELEVIDYS Label Changes and Heightened Safety Warnings","media":"Simply Wall St.","content":"<div>\n<p>Sarepta Therapeutics (SRPT) announced major updates to the prescribing information for its gene therapy ELEVIDYS. These updates include a new boxed warning for acute serious liver injury risk and the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sarepta-therapeutics-srpt-valuation-update-following-elevidy\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta Therapeutics (SRPT): Valuation Update Following ELEVIDYS Label Changes and Heightened Safety Warnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta Therapeutics (SRPT): Valuation Update Following ELEVIDYS Label Changes and Heightened Safety Warnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-22 15:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sarepta-therapeutics-srpt-valuation-update-following-elevidy><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sarepta Therapeutics (SRPT) announced major updates to the prescribing information for its gene therapy ELEVIDYS. These updates include a new boxed warning for acute serious liver injury risk and the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sarepta-therapeutics-srpt-valuation-update-following-elevidy\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sarepta-therapeutics-srpt-valuation-update-following-elevidy","article_id":"2585179658","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sarepta-therapeutics-srpt-valuation-update-following-elevidy","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2585179658","pubTimestamp":1763796098,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sarepta Therapeutics (SRPT) announced major updates to the prescribing information for its gene therapy ELEVIDYS. These updates include a new boxed warning for acute serious liver injury risk and the removal of its non-ambulatory indication.\nSee our latest analysis for Sarepta Therapeutics.\n\nSarepta Therapeutics' latest prescribing changes for ELEVIDYS come amid a turbulent year, with heightened regulatory scrutiny piling onto already steep challenges. After a steep slide, Sarepta’s share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4139":"生物科技","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","SRPT":"Sarepta Therapeutics","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC"},"translate_title":"Sarepta Therapeutics(SRPT)：ELEVIDYS标签变更和加强安全警告后的估值更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1.5},"content_text":"Sarepta Therapeutics (SRPT) announced major updates to the prescribing information for its gene therapy ELEVIDYS. These updates include a new boxed warning for acute serious liver injury risk and the removal of its non-ambulatory indication. See our latest analysis for Sarepta Therapeutics.  Sarepta Therapeutics' latest prescribing changes for ELEVIDYS come amid a turbulent year, with heightened regulatory scrutiny piling onto already steep challenges. After a steep slide, Sarepta’s share price tumbled more than 85% year-to-date and its one-year total shareholder return stands at negative 84.5%. Recent regulatory updates have added to investor uncertainty, overshadowing any short-term bounce. Momentum has clearly faded, underscoring how rapid shifts in risk perception can reshape this biotech’s outlook almost overnight.\n  If this kind of volatility has you thinking about diversification, now’s the perfect time to explore innovation-driven peers using our free healthcare stocks screener: See the full list for free.   Given such a sharp decline in Sarepta’s share price, investors may wonder if the market is overlooking the company’s future prospects or if ongoing risks are already fully reflected at today’s levels, leaving little room for a meaningful rebound.\n AdvertisementMost Popular Narrative: 17.9% Undervalued  Sarepta Therapeutics’ most-followed narrative points to a fair value of $21.55 per share, a significant premium to the last close at $17.69. With sentiment split and new clinical data on the horizon, debate is intensifying over what is driving the estimated upside for SRPT.\n   Efforts to balance demand across affiliated treatment centers with additional capacity could improve the ability to treat more patients. This may advance revenue growth as these centers become more effective and productive in patient throughput. The scheduled dissemination of additional safety and efficacy data for ELEVIDYS, along with anticipated label updates for new patient populations, provides clear pathways to further demonstrate the therapy’s positive risk-benefit. This could likely enhance long-term revenue drivers.\n  Read the complete narrative.  Curious which numbers are causing analysts to forecast a turnaround? A bold profit margin leap, changing patient access, and rapid portfolio expansion shape this narrative’s fair value math. Want to see the hidden drivers setting SRPT apart from its biotech peers? Find out what could make this recovery story more than just a rebound.\n Result: Fair Value of $21.55 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, significant safety events or persistent treatment delays could quickly undermine confidence in Sarepta's recovery outlook and challenge the bullish narrative. Find out about the key risks to this Sarepta Therapeutics narrative.  Build Your Own Sarepta Therapeutics Narrative  If you have a different take or want to dive into the figures yourself, you can craft your own narrative in just a few minutes: Do it your way.  A great starting point for your Sarepta Therapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Ready for More Winning Ideas?  The market never stands still, and smart investors always have an eye on the next opportunity. Don’t let another breakout stock slip past. Unlock tailored investment angles and find your next confidence-boosting buy:\n  Tap into potential with high-yield income picks by checking out these 17 dividend stocks with yields > 3% and see which companies deliver consistent returns even when markets get volatile. Spot fast-moving trends as you power up your watchlist with these 25 AI penny stocks poised to benefit from AI innovation across multiple sectors. Strengthen your portfolio by acting early on these 917 undervalued stocks based on cash flows. See which opportunities may be flying under most investors’ radars right now.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585179658","isCrawlerRequest":true}